TY  - JOUR
AU  - Dimić-Janjić, Sanja
AU  - Hoda, Mir Alireza
AU  - Milenković, Branislava
AU  - Kotur-Stevuljević, Jelena
AU  - Stjepanović, Mihailo
AU  - Gompelmann, Daniela
AU  - Janković, Jelena
AU  - Miljković, Milica
AU  - Milin-Lazović, Jelena
AU  - Đurđević, Nataša
AU  - Marić, Dragana
AU  - Milivojević, Ivan
AU  - Popević, Spasoje
PY  - 2023
UR  - https://farfar.pharmacy.bg.ac.rs/handle/123456789/4612
AB  - Background: Inflammation, oxidative stress and an imbalance between proteases and protease inhibitors are recognized pathophysiological features of chronic obstructive pulmonary disease (COPD). The aim of this study was to evaluate serum levels of matrix metalloproteinase-9 (MMP-9) and tissue inhibitor of metalloproteinase-1 (TIMP-1) in patients with COPD and to assess their relationship with lung function, symptom severity scores and recent acute exacerbations. Methods: In this observational cohort study, serum levels of MMP-9 and TIMP-1 and the MMP-9/TIMP-1 ratio in the peripheral blood of COPD patients with stable disease and healthy controls were determined, and their association with lung function (postbronchodilator spirometry, body plethysmography, single breath diffusion capacity for carbon monoxide), symptom severity scores (mMRC and CAT) and exacerbation history were assessed. Results: COPD patients (n = 98) had significantly higher levels of serum MMP-9 and TIMP-1 and a higher MMP-9/TIMP-1 ratio than healthy controls (n = 47) (p ≤ 0.001). The areas under the receiver operating characteristic curve for MMP-9, TIMP-1 and the MMP-9/TIMP-1 ratio for COPD diagnosis were 0.974, 0.961 and 0.910, respectively (all p < 0.05). MMP-9 and the MMP-9/TIMP-1 ratio were both negatively correlated with FVC, FEV1, FEV1/FVC, VC, and IC (all p < 0.05). For MMP-9, a positive correlation was found with RV/TLC% (p = 0.005), and a positive correlation was found for the MMP-9/TIMP-1 ratio with RV% and RV/TLC% (p = 0.013 and 0.002, respectively). Patients with COPD GOLD 3 and 4 presented greater MMP-9 levels and a greater MMP-9/TIMP-1 ratio compared to GOLD 1 and 2 patients (p ≤ 0.001). No correlation between diffusion capacity for carbon monoxide and number of acute exacerbations in the previous year was found. Conclusions: COPD patients have elevated serum levels of MMP-9 and TIMP-1 and MMP-9/TIMP-1 ratio. COPD patients have an imbalance between MMP-9 and TIMP-1 in favor of a pro-proteolytic environment, which overall indicates the importance of the MMP-9/TIMP-1 ratio as a potential biomarker for COPD diagnosis and severity.
PB  - BioMed Central Ltd
T2  - European Journal of Medical Research
T1  - The usefulness of MMP-9, TIMP-1 and MMP-9/TIMP-1 ratio for diagnosis and assessment of COPD severity
VL  - 28
IS  - 1
DO  - 10.1186/s40001-023-01094-7
ER  - 

@article{
author = "Dimić-Janjić, Sanja and Hoda, Mir Alireza and Milenković, Branislava and Kotur-Stevuljević, Jelena and Stjepanović, Mihailo and Gompelmann, Daniela and Janković, Jelena and Miljković, Milica and Milin-Lazović, Jelena and Đurđević, Nataša and Marić, Dragana and Milivojević, Ivan and Popević, Spasoje",
year = "2023",
abstract = "Background: Inflammation, oxidative stress and an imbalance between proteases and protease inhibitors are recognized pathophysiological features of chronic obstructive pulmonary disease (COPD). The aim of this study was to evaluate serum levels of matrix metalloproteinase-9 (MMP-9) and tissue inhibitor of metalloproteinase-1 (TIMP-1) in patients with COPD and to assess their relationship with lung function, symptom severity scores and recent acute exacerbations. Methods: In this observational cohort study, serum levels of MMP-9 and TIMP-1 and the MMP-9/TIMP-1 ratio in the peripheral blood of COPD patients with stable disease and healthy controls were determined, and their association with lung function (postbronchodilator spirometry, body plethysmography, single breath diffusion capacity for carbon monoxide), symptom severity scores (mMRC and CAT) and exacerbation history were assessed. Results: COPD patients (n = 98) had significantly higher levels of serum MMP-9 and TIMP-1 and a higher MMP-9/TIMP-1 ratio than healthy controls (n = 47) (p ≤ 0.001). The areas under the receiver operating characteristic curve for MMP-9, TIMP-1 and the MMP-9/TIMP-1 ratio for COPD diagnosis were 0.974, 0.961 and 0.910, respectively (all p < 0.05). MMP-9 and the MMP-9/TIMP-1 ratio were both negatively correlated with FVC, FEV1, FEV1/FVC, VC, and IC (all p < 0.05). For MMP-9, a positive correlation was found with RV/TLC% (p = 0.005), and a positive correlation was found for the MMP-9/TIMP-1 ratio with RV% and RV/TLC% (p = 0.013 and 0.002, respectively). Patients with COPD GOLD 3 and 4 presented greater MMP-9 levels and a greater MMP-9/TIMP-1 ratio compared to GOLD 1 and 2 patients (p ≤ 0.001). No correlation between diffusion capacity for carbon monoxide and number of acute exacerbations in the previous year was found. Conclusions: COPD patients have elevated serum levels of MMP-9 and TIMP-1 and MMP-9/TIMP-1 ratio. COPD patients have an imbalance between MMP-9 and TIMP-1 in favor of a pro-proteolytic environment, which overall indicates the importance of the MMP-9/TIMP-1 ratio as a potential biomarker for COPD diagnosis and severity.",
publisher = "BioMed Central Ltd",
journal = "European Journal of Medical Research",
title = "The usefulness of MMP-9, TIMP-1 and MMP-9/TIMP-1 ratio for diagnosis and assessment of COPD severity",
volume = "28",
number = "1",
doi = "10.1186/s40001-023-01094-7"
}

Dimić-Janjić, S., Hoda, M. A., Milenković, B., Kotur-Stevuljević, J., Stjepanović, M., Gompelmann, D., Janković, J., Miljković, M., Milin-Lazović, J., Đurđević, N., Marić, D., Milivojević, I.,& Popević, S.. (2023). The usefulness of MMP-9, TIMP-1 and MMP-9/TIMP-1 ratio for diagnosis and assessment of COPD severity. in European Journal of Medical Research
BioMed Central Ltd., 28(1).
https://doi.org/10.1186/s40001-023-01094-7

Dimić-Janjić S, Hoda MA, Milenković B, Kotur-Stevuljević J, Stjepanović M, Gompelmann D, Janković J, Miljković M, Milin-Lazović J, Đurđević N, Marić D, Milivojević I, Popević S. The usefulness of MMP-9, TIMP-1 and MMP-9/TIMP-1 ratio for diagnosis and assessment of COPD severity. in European Journal of Medical Research. 2023;28(1).
doi:10.1186/s40001-023-01094-7 .

Dimić-Janjić, Sanja, Hoda, Mir Alireza, Milenković, Branislava, Kotur-Stevuljević, Jelena, Stjepanović, Mihailo, Gompelmann, Daniela, Janković, Jelena, Miljković, Milica, Milin-Lazović, Jelena, Đurđević, Nataša, Marić, Dragana, Milivojević, Ivan, Popević, Spasoje, "The usefulness of MMP-9, TIMP-1 and MMP-9/TIMP-1 ratio for diagnosis and assessment of COPD severity" in European Journal of Medical Research, 28, no. 1 (2023),
https://doi.org/10.1186/s40001-023-01094-7 . .

TY  - JOUR
AU  - Milenković, Branislava
AU  - Dimić Janjić, Sanja
AU  - Kotur-Stevuljević, Jelena
AU  - Kopitović, Ivan
AU  - Janković, Jelena
AU  - Stjepanović, Mihailo
AU  - Vukoja, Marija
AU  - Ristić, Snežana
AU  - Davičević-Elez, Žaklina
PY  - 2020
UR  - https://farfar.pharmacy.bg.ac.rs/handle/123456789/3591
AB  - Uvod/Cilj. Upitnik za procenu hronične opstruktivne bolesti pluća (HOBP) (engl. COPD Assessment Test - CAT) je jednostavan i pouzdan test namenjen za merenje ukupnog zdravstvenog stanja bolesnika sa HOBP i koristan je za upotrebu u svakodnevnoj kliničkoj praksi. Cilj ovog istraživanja bio je da se proceni validnost i opravdanost primene srpske verzije CAT. Metode. U studiji je učestvovalo 140 bolesnika u stabilnom stanju HOBP, ispitivanih u ambulantnim uslovima na Klinici za pulmologiju, Kliničkog centra Srbije u Beogradu i Institutu za plućne bolesti Vojvodine u Sremskoj Kamenici. Tokom prvog pregleda bolesnicima je učinjeno ispitivanje plućne funkcije (spirometrija), popunili su CAT upitnik i mMMR (modified Medical Research Council) skalu za procenu stepena dispneje. Pouzdanost CAT test-retesta je ispitivana kod 20 bolesnika od strane istog istraživača. Rezultati. Pokazali smo da srpska verzija CAT ima visoku internu konzistentnost sa Cronbach-ovim alfa 0.88. Test-retest analiza pokazala je dobru korelaciju između CAT rezultata u dve vremenske tačke (Spearmanov r = 0,681; p < 0,01). CAT je umereno korelirao sa mMRC skalom (r = + 0,57), blago sa forsiranim ekspiratornim volumenom u prvoj sekundi (FEV1), (r -0,214), uz pozitivnu korelaciju sa ukupnim brojem pogoršanja HOBP, ali bez jasne regularnosti sa promenom GOLD (Global Initiative for Chronic Obstructive Lung Disease) stadijuma. Zaključak. Srpska verzija CAT je pokazala visoku internu konzistentnost i test-retest pouzdanost. Ona predstavlja pouzdano, jednostavno i lako sredstvo za upotrebu koje se može koristiti u svakodnevnoj kliničkoj praksi za procenu zdravstvenog stanja kod bolesnika sa HOBP u Srbiji.
AB  - Background/Aim.  The  Chronic  obstructive  pulmonary  disease  (COPD)  Assessment  Test  (CAT)  is  a  simple  and  reliable  tool  designed  to  measure  overall  COPD  related  health  status  and  complement  physician  assessment  in  rou-tine clinical practice. Objective of this study was to evaluate the validity of the Serbian version of CAT. Methods. Study included  140  outpatients  in  the  stable  COPD,  recruited  from  two  centres:  Clinic  for  Pulmonology,  Clinical  Center  of Serbia, Belgrade, and Institute for Pulmonary Diseases of Vojvodina,   Sremska   Kamenica.   All   patients   completed   pulmonary  function  testing  –  spirometry,  the  CAT  and  the  modified Medical Research Council (mMRC) dyspnea scale at baseline visit. The CAT test-retest reliability was tested in 20  patients  by  the  same  investigator  (physician).  Results.We  demonstrated  that  Serbian  version  of  CAT  had  high internal consistency with Cronbach’s alpha 0.88. Test-retest analysis  showed  good  correlation  between  CAT  scores  in  two  time  points  (Spearman’s  ρ  =  0.681,  p <  0.01).  In  our  study  the  CAT  correlated  moderately  to  mMRC  scale  (ρ  =  +0.57), weakly to FEV1 (ρ -0.214), was positively related to number   of   exacerbations,   but   did   not   showed   exact   regularity  with  change  in  the  Global  Initiative  for  Chronic  Obstructive  lung  disease  (GOLD)  stage.  Conclusion.The Serbian version of CAT is a reliable, simple and easy-to-use tool that can be used in everyday clinical practice to assess the health status of COPD patients in Serbia.
PB  - Beograd : Vojnomedicinska akademija - Institut za naučne informacije
T2  - Vojnosanitetski pregled
T1  - Validation of Serbian version of chronic obstructive pulmonary disease assessment test
T1  - Validacija sprske verzije upitnika za procenu hronične opstruktivne bolesti pluća
VL  - 77
IS  - 3
SP  - 294
EP  - 299
DO  - 10.2298/VSP180220094M
ER  - 

@article{
author = "Milenković, Branislava and Dimić Janjić, Sanja and Kotur-Stevuljević, Jelena and Kopitović, Ivan and Janković, Jelena and Stjepanović, Mihailo and Vukoja, Marija and Ristić, Snežana and Davičević-Elez, Žaklina",
year = "2020",
abstract = "Uvod/Cilj. Upitnik za procenu hronične opstruktivne bolesti pluća (HOBP) (engl. COPD Assessment Test - CAT) je jednostavan i pouzdan test namenjen za merenje ukupnog zdravstvenog stanja bolesnika sa HOBP i koristan je za upotrebu u svakodnevnoj kliničkoj praksi. Cilj ovog istraživanja bio je da se proceni validnost i opravdanost primene srpske verzije CAT. Metode. U studiji je učestvovalo 140 bolesnika u stabilnom stanju HOBP, ispitivanih u ambulantnim uslovima na Klinici za pulmologiju, Kliničkog centra Srbije u Beogradu i Institutu za plućne bolesti Vojvodine u Sremskoj Kamenici. Tokom prvog pregleda bolesnicima je učinjeno ispitivanje plućne funkcije (spirometrija), popunili su CAT upitnik i mMMR (modified Medical Research Council) skalu za procenu stepena dispneje. Pouzdanost CAT test-retesta je ispitivana kod 20 bolesnika od strane istog istraživača. Rezultati. Pokazali smo da srpska verzija CAT ima visoku internu konzistentnost sa Cronbach-ovim alfa 0.88. Test-retest analiza pokazala je dobru korelaciju između CAT rezultata u dve vremenske tačke (Spearmanov r = 0,681; p < 0,01). CAT je umereno korelirao sa mMRC skalom (r = + 0,57), blago sa forsiranim ekspiratornim volumenom u prvoj sekundi (FEV1), (r -0,214), uz pozitivnu korelaciju sa ukupnim brojem pogoršanja HOBP, ali bez jasne regularnosti sa promenom GOLD (Global Initiative for Chronic Obstructive Lung Disease) stadijuma. Zaključak. Srpska verzija CAT je pokazala visoku internu konzistentnost i test-retest pouzdanost. Ona predstavlja pouzdano, jednostavno i lako sredstvo za upotrebu koje se može koristiti u svakodnevnoj kliničkoj praksi za procenu zdravstvenog stanja kod bolesnika sa HOBP u Srbiji., Background/Aim.  The  Chronic  obstructive  pulmonary  disease  (COPD)  Assessment  Test  (CAT)  is  a  simple  and  reliable  tool  designed  to  measure  overall  COPD  related  health  status  and  complement  physician  assessment  in  rou-tine clinical practice. Objective of this study was to evaluate the validity of the Serbian version of CAT. Methods. Study included  140  outpatients  in  the  stable  COPD,  recruited  from  two  centres:  Clinic  for  Pulmonology,  Clinical  Center  of Serbia, Belgrade, and Institute for Pulmonary Diseases of Vojvodina,   Sremska   Kamenica.   All   patients   completed   pulmonary  function  testing  –  spirometry,  the  CAT  and  the  modified Medical Research Council (mMRC) dyspnea scale at baseline visit. The CAT test-retest reliability was tested in 20  patients  by  the  same  investigator  (physician).  Results.We  demonstrated  that  Serbian  version  of  CAT  had  high internal consistency with Cronbach’s alpha 0.88. Test-retest analysis  showed  good  correlation  between  CAT  scores  in  two  time  points  (Spearman’s  ρ  =  0.681,  p <  0.01).  In  our  study  the  CAT  correlated  moderately  to  mMRC  scale  (ρ  =  +0.57), weakly to FEV1 (ρ -0.214), was positively related to number   of   exacerbations,   but   did   not   showed   exact   regularity  with  change  in  the  Global  Initiative  for  Chronic  Obstructive  lung  disease  (GOLD)  stage.  Conclusion.The Serbian version of CAT is a reliable, simple and easy-to-use tool that can be used in everyday clinical practice to assess the health status of COPD patients in Serbia.",
publisher = "Beograd : Vojnomedicinska akademija - Institut za naučne informacije",
journal = "Vojnosanitetski pregled",
title = "Validation of Serbian version of chronic obstructive pulmonary disease assessment test, Validacija sprske verzije upitnika za procenu hronične opstruktivne bolesti pluća",
volume = "77",
number = "3",
pages = "294-299",
doi = "10.2298/VSP180220094M"
}

Milenković, B., Dimić Janjić, S., Kotur-Stevuljević, J., Kopitović, I., Janković, J., Stjepanović, M., Vukoja, M., Ristić, S.,& Davičević-Elez, Ž.. (2020). Validation of Serbian version of chronic obstructive pulmonary disease assessment test. in Vojnosanitetski pregled
Beograd : Vojnomedicinska akademija - Institut za naučne informacije., 77(3), 294-299.
https://doi.org/10.2298/VSP180220094M

Milenković B, Dimić Janjić S, Kotur-Stevuljević J, Kopitović I, Janković J, Stjepanović M, Vukoja M, Ristić S, Davičević-Elez Ž. Validation of Serbian version of chronic obstructive pulmonary disease assessment test. in Vojnosanitetski pregled. 2020;77(3):294-299.
doi:10.2298/VSP180220094M .

Milenković, Branislava, Dimić Janjić, Sanja, Kotur-Stevuljević, Jelena, Kopitović, Ivan, Janković, Jelena, Stjepanović, Mihailo, Vukoja, Marija, Ristić, Snežana, Davičević-Elez, Žaklina, "Validation of Serbian version of chronic obstructive pulmonary disease assessment test" in Vojnosanitetski pregled, 77, no. 3 (2020):294-299,
https://doi.org/10.2298/VSP180220094M . .

TY  - JOUR
AU  - Popević, Spasoje
AU  - Šumarac, Zorica
AU  - Jovanović, Dragana
AU  - Babić, Dragan
AU  - Stjepanović, Mihailo
AU  - Jovičić, Snežana
AU  - Sobić-Saranović, Dragana
AU  - Filipović, Snežana
AU  - Gvozdenović, Branko
AU  - Omcikus, Maja
AU  - Milovanović, Andela
AU  - Videnović-Ivanov, Jelica
AU  - Radović, Ana
AU  - Zugić, Vladimir
AU  - Vučinić-Mihailović, Violeta
PY  - 2016
UR  - https://farfar.pharmacy.bg.ac.rs/handle/123456789/2749
AB  - Background: Until now, a proper biomarker(s) to evaluate sarcoidosis activity has not been recognized. The aims of this study were to evaluate the sensitivity and specificity of the two biomarkers of sarcoidosis activity already in use (serum angiotensin converting enzyme - ACE and serum chitotriosidase) in a population of 430 sarcoidosis patients. The activities of these markers were also analyzed in a group of 264 healthy controls. Methods: Four hundred and thirty biopsy positive sarcoidosis patients were divided into groups with active and inactive disease, and groups with acute or chronic disease. In a subgroup of 55 sarcoidosis patients, activity was also assessed by F-18 fluorodeoxyglucose positron emission tomography (F-18-FDG-PET) scanning. Both serum chitotriosidase and ACE levels showed non-normal distribution, so nonparametric tests were used in statistical analysis. Results: Serum chitotriosidase activities were almost 6 times higher in patients with active sarcoidosis than in healthy controls and inactive disease. A serum chitotriosidase value of 100 nmol/mL/h had the sensitivity of 82.5% and specificity of 70.0%. A serum ACE activity cutoff value of 32.0 U/L had the sensitivity of 66.0% and the specificity of 54%. A statistically significant correlation was obtained between the focal granulomatous activity detected on F-18-FDG PET/CT and serum chitotriosidase levels, but no such correlation was found with ACE. The levels of serum chitotriosidase activity significantly correlated with the disease duration (P lt 0.0001). Also, serum chitotriosidase significantly correlated with clinical outcome status (COS) categories (rho=0.272, P=0.001). Conclusions: Serum chitotriosidase proved to be a reliable biomarker of sarcoidosis activity and disease chronicity.
PB  - Društvo medicinskih biohemičara Srbije, Beograd i Versita
T2  - Journal of Medical Biochemistry
T1  - Verifying Sarcoidosis Activity: Chitotriosidase Versus ACE in Sarcoidosis - A Case-Control Study
VL  - 35
IS  - 4
SP  - 390
EP  - 400
DO  - 10.1515/jomb-2016-0017
ER  - 

@article{
author = "Popević, Spasoje and Šumarac, Zorica and Jovanović, Dragana and Babić, Dragan and Stjepanović, Mihailo and Jovičić, Snežana and Sobić-Saranović, Dragana and Filipović, Snežana and Gvozdenović, Branko and Omcikus, Maja and Milovanović, Andela and Videnović-Ivanov, Jelica and Radović, Ana and Zugić, Vladimir and Vučinić-Mihailović, Violeta",
year = "2016",
abstract = "Background: Until now, a proper biomarker(s) to evaluate sarcoidosis activity has not been recognized. The aims of this study were to evaluate the sensitivity and specificity of the two biomarkers of sarcoidosis activity already in use (serum angiotensin converting enzyme - ACE and serum chitotriosidase) in a population of 430 sarcoidosis patients. The activities of these markers were also analyzed in a group of 264 healthy controls. Methods: Four hundred and thirty biopsy positive sarcoidosis patients were divided into groups with active and inactive disease, and groups with acute or chronic disease. In a subgroup of 55 sarcoidosis patients, activity was also assessed by F-18 fluorodeoxyglucose positron emission tomography (F-18-FDG-PET) scanning. Both serum chitotriosidase and ACE levels showed non-normal distribution, so nonparametric tests were used in statistical analysis. Results: Serum chitotriosidase activities were almost 6 times higher in patients with active sarcoidosis than in healthy controls and inactive disease. A serum chitotriosidase value of 100 nmol/mL/h had the sensitivity of 82.5% and specificity of 70.0%. A serum ACE activity cutoff value of 32.0 U/L had the sensitivity of 66.0% and the specificity of 54%. A statistically significant correlation was obtained between the focal granulomatous activity detected on F-18-FDG PET/CT and serum chitotriosidase levels, but no such correlation was found with ACE. The levels of serum chitotriosidase activity significantly correlated with the disease duration (P lt 0.0001). Also, serum chitotriosidase significantly correlated with clinical outcome status (COS) categories (rho=0.272, P=0.001). Conclusions: Serum chitotriosidase proved to be a reliable biomarker of sarcoidosis activity and disease chronicity.",
publisher = "Društvo medicinskih biohemičara Srbije, Beograd i Versita",
journal = "Journal of Medical Biochemistry",
title = "Verifying Sarcoidosis Activity: Chitotriosidase Versus ACE in Sarcoidosis - A Case-Control Study",
volume = "35",
number = "4",
pages = "390-400",
doi = "10.1515/jomb-2016-0017"
}

Popević, S., Šumarac, Z., Jovanović, D., Babić, D., Stjepanović, M., Jovičić, S., Sobić-Saranović, D., Filipović, S., Gvozdenović, B., Omcikus, M., Milovanović, A., Videnović-Ivanov, J., Radović, A., Zugić, V.,& Vučinić-Mihailović, V.. (2016). Verifying Sarcoidosis Activity: Chitotriosidase Versus ACE in Sarcoidosis - A Case-Control Study. in Journal of Medical Biochemistry
Društvo medicinskih biohemičara Srbije, Beograd i Versita., 35(4), 390-400.
https://doi.org/10.1515/jomb-2016-0017

Popević S, Šumarac Z, Jovanović D, Babić D, Stjepanović M, Jovičić S, Sobić-Saranović D, Filipović S, Gvozdenović B, Omcikus M, Milovanović A, Videnović-Ivanov J, Radović A, Zugić V, Vučinić-Mihailović V. Verifying Sarcoidosis Activity: Chitotriosidase Versus ACE in Sarcoidosis - A Case-Control Study. in Journal of Medical Biochemistry. 2016;35(4):390-400.
doi:10.1515/jomb-2016-0017 .

Popević, Spasoje, Šumarac, Zorica, Jovanović, Dragana, Babić, Dragan, Stjepanović, Mihailo, Jovičić, Snežana, Sobić-Saranović, Dragana, Filipović, Snežana, Gvozdenović, Branko, Omcikus, Maja, Milovanović, Andela, Videnović-Ivanov, Jelica, Radović, Ana, Zugić, Vladimir, Vučinić-Mihailović, Violeta, "Verifying Sarcoidosis Activity: Chitotriosidase Versus ACE in Sarcoidosis - A Case-Control Study" in Journal of Medical Biochemistry, 35, no. 4 (2016):390-400,
https://doi.org/10.1515/jomb-2016-0017 . .